Okay, so Boxer Capital Management just dropped $15.15 million on 375,000 shares of Terns Pharmaceuticals (TERN +1.32%). That’s… a lot of money. It’s enough to make even me consider a vacation, and believe me, I’ve priced out several. They picked these up during Q4, which, let’s be honest, feels like three quarters ago at this point. The market’s been a little… enthusiastic lately.
What Does This Even Mean?
Boxer Capital now owns 3.32% of Terns, which, in the grand scheme of a $456.88 million portfolio, is… noticeable. It’s like adding a really good side dish to a perfectly adequate meal. Their top holdings? TNGX ($96.36M), RVMD ($31.86M), KOD ($31.76M), KYMR ($25.61M), and CELC ($22.44M). Basically, they’re all in on the alphabet soup of biotech.
And the stock? Up 858.4% over the last year. EIGHT HUNDRED AND FIFTY-EIGHT PERCENT. Look, I’ve seen good returns, but that’s bordering on irresponsible exuberance. It’s outperforming the S&P 500 by, get this, 862.96 percentage points. I’m starting to think I should have become a liver disease researcher.
Terns: The Details (Because We Have to Have Details)
Here’s the quick and dirty. Terns is a clinical-stage biopharmaceutical company, which is corporate-speak for “we’re working on stuff, and it might work.” They’re focused on NASH (non-alcoholic steatohepatitis) and obesity, because apparently, we need more options for those. Their pipeline includes TERN-101, TERN-201, TERN-501, and TERN-601. I’m not even going to try to remember those. They have 59 employees. That’s… cozy.
| Metric | Value |
|---|---|
| Price (as of 2/17/26) | $39.58 |
| Market capitalization | $3.57 billion |
| Employees | 59 |
| One-year price change | 858.35% |
Okay, So What’s My Take?
Look, I’m not saying Terns is a bad investment. But let’s be real: biotech is a volatile sector. One bad clinical trial result and that 858% gain could vanish faster than my weekend. Individual stocks are fine if you enjoy emotional rollercoasters. If you prefer a slightly more… sedate experience, a biotech ETF might be a better fit.
The VanEck Biotech ETF (NYSEMKT: BBH) is a solid option. It’s like a diversified portfolio of tiny science experiments, and it only costs 0.35% in expenses. Which, frankly, is less than I spend on caffeine each month. It spreads the risk, so you’re not relying on one company to cure… everything.
Bottom line? Boxer Capital made a bet. It’s a big bet. And honestly? I’m just hoping they have a good risk management team. Because I need to go refill my coffee. And maybe look into a career change.
Read More
- Gold Rate Forecast
- DOT PREDICTION. DOT cryptocurrency
- Silver Rate Forecast
- 4 Reasons to Buy Interactive Brokers Stock Like There’s No Tomorrow
- Top 15 Insanely Popular Android Games
- EUR UAH PREDICTION
- Did Alan Cumming Reveal Comic-Accurate Costume for AVENGERS: DOOMSDAY?
- ELESTRALS AWAKENED Blends Mythology and POKÉMON (Exclusive Look)
- Core Scientific’s Merger Meltdown: A Gogolian Tale
- New ‘Donkey Kong’ Movie Reportedly in the Works with Possible Release Date
2026-03-05 18:03